Ernest Loumaye, ObsEva CEO (ObsEva)
ObsEva’s second uterine fibroids PhIII comes through, sending some investors to the hills
In the three-company race to develop a new uterine fibroid treatment, ObsEva long lagged behind AbbVie and Myovant. Still, they hoped that better efficacy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.